Skip to main content
OpenTrials

Clinical trial condition

Demyelinating Diseases

Explore clinical trials studying Demyelinating Diseases. Study availability and eligibility vary by location and protocol.

2,928 public trials 460 recruiting studies
Refine in advanced search Browse all conditions

Demyelinating Diseases trial results

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • TG Therapeutics Investigational Trial Site Birmingham, Alabama, United States
  • TG Therapeutics Investigational Trial Site Huntsville, Alabama, United States
  • TG Therapeutics Investigational Trial Site Mobile, Alabama, United States
  • TG Therapeutics Investigational Trial Site Gilbert, Arizona, United States
View all 91 locations
View Trial Details
Recruiting

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

NCT06143514

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • PROVIDE Virtual Research Coordination Center San Francisco, California, United States
  • PROVIDE Virtual Research Coordination Center Smyrna, Georgia, United States
  • TG Therapeutics Investigational Trial Site Boston, Massachusetts, United States
  • PROVIDE Virtual Research Coordination Center Wilmington, North Carolina, United States
View Trial Details
Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

NCT07503873

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +4 more
Locations
  • TG Therapeutics Investigational Trial Site Bihać, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site Sarajevo, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site Tuzla, Bosnia and Herzegovina
  • TG Therapeutics Investigational Trial Site Zenica, Bosnia and Herzegovina
View all 39 locations
View Trial Details
Recruiting

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

NCT06780150

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +4 more
Locations
  • Uniklinik RWTH Aachen Aachen, Germany
  • Gesundheitszentrum St. Marien GmbH Amberg, Germany
  • Sächsisches Krankenhaus Arnsdorf Arnsdorf, Germany
  • Neuropraxis im Stadtpalais Dres. Ulzheimer/Herröder/Wessig GbR Aschaffenburg, Germany
View all 92 locations
View Trial Details

Related conditions